WJ-PURE is under clinical development by Vitti Labs and currently in Phase I for Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WJ-PURE’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WJ-PURE is under development for the treatment of Alzheimer's disease, chronic obstructive pulmonary disease (COPD), osteoarthritis, COVID induced pulmonary fibrosis, COVID-19 associated acute respiratory distress syndrome and Duchenne muscular dystrophy. The therapeutic candidate comprises umbilical cord derived mesenchymal stem cells.
Vitti Labs overview
Vitti Labs is focused on life science research, development and manufacturing. Vitti Labs is headquartered in Liberty, Missouri, the US.
For a complete picture of WJ-PURE’s drug-specific PTSR and LoA scores, buy the report here.